Michel Lagarde, President and CEO of West Pharmaceutical Services Inc, filed a Form 4 on September 10, 2026, disclosing the acquisition of stock options and restricted stock units granted on September 8, 2026.
A Form 4 filed on September 10, 2026 disclosed that Jarrett R. Lilien, President and Chief Operating Officer of WisdomTree, Inc. (NYSE:WT), sold 30,000 shares of common stock on September 9, 2026 under a pre-established Rule 10b5-1 trading plan.
Once known for early-stage antibiotics and probiotics work, Oragenics Inc (NYSE American:OGEN) has reinvented itself as a neuroscience-focused developer built around intranasal drug delivery for brain injury. The company, listed on NYSE American under the ticker OGEN, is a sub-dollar micro-cap advancing a mid-stage …
● A single-session dip of around 5% barely registers as news for a development-stage biotech, and in the case of OKYO Pharma the recent slide arrives against an otherwise constructive backdrop.
● Oncolytics Biotech is a Calgary-based, Nasdaq-listed clinical-stage biotechnology company developing pelareorep, an intravenously administered formulation of a reovirus designed to stimulate an anti-tumor immune response.
● The modest one-day rise does not map to a single confirmed same-session catalyst; at fractions of a cent, OTLC moves are heavily influenced by thin liquidity.
OncoVista Innovative Therapies, Inc. (OTC:OVIT) is one of those names that lingers on quote screens long after the working company behind it has gone quiet. Once a San Antonio-based clinical-stage pharmaceutical developer with ambitions in oncology, OncoVista today trades as a sub-penny shell, priced …
● Despite If anything, attention around Prestige has centered on its acquisition-driven growth strategy and the addedLeveragefrom the senior notes offering.
PDS Biotechnology Corporation (NASDAQ:PDSB) has spent 2026 trying to prove that its lead cancer immunotherapy can reach the market faster, even as its share price has slid toward penny-stock territory. The supplied headline frames a "drift lower" and asks whether the pullback is creating …
● Commercial-stage biopharma stocks can be punished even when sales are climbing, and Phathom Pharmaceuticals has felt that tension in 2026.